117 related articles for article (PubMed ID: 27089817)
1. Long-lasting hypoglycemic effect of modified FGF-21 analog with polyethylene glycol in type 1 diabetic mice and its systematic toxicity.
Ye X; Qi J; Wu Q; Yu D; Li S; Wu Y; Li D
Eur J Pharmacol; 2016 Jun; 781():198-208. PubMed ID: 27089817
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation.
Ye X; Qi J; Sun G; Ren G; Zhu S; Wu Y; Yu D; Zhao J; Liu M; Li D
Curr Pharm Biotechnol; 2013; 14(15):1287-98. PubMed ID: 25106652
[TBL] [Abstract][Full Text] [Related]
3. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol.
Huang Z; Wang H; Lu M; Sun C; Wu X; Tan Y; Ye C; Zhu G; Wang X; Cai L; Li X
PLoS One; 2011; 6(6):e20669. PubMed ID: 21673953
[TBL] [Abstract][Full Text] [Related]
4. Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice.
Ye X; Qi J; Ren G; Xu P; Wu Y; Zhu S; Yu D; Li S; Wu Q; Muhi RL; Li D
Endocrine; 2015 Aug; 49(3):683-92. PubMed ID: 25557015
[TBL] [Abstract][Full Text] [Related]
5. [The long lasting effect of the murine fibroblast growth factor-21 on blood glucose control of diabetic animals].
Zhao JZ; Sun GP; Ye XL; Li JN; Ren GP; Wang WF; Liu MY; Li DS
Yao Xue Xue Bao; 2013 Mar; 48(3):352-8. PubMed ID: 23724647
[TBL] [Abstract][Full Text] [Related]
6. Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice.
Ye X; Qi J; Wu Y; Yu D; Xu P; Li S; Zhu S; Wu Q; Ren G; Li D
Diabetes Metab; 2015 Feb; 41(1):82-90. PubMed ID: 25451186
[TBL] [Abstract][Full Text] [Related]
7. Pilot-scale production and characterization of PEGylated human FGF-21 analog.
Ye X; Qi J; Yu D; Li S; Wu Q; Wu Y; Ren G; Han J; Li D
J Biotechnol; 2016 Jun; 228():8-17. PubMed ID: 27109774
[TBL] [Abstract][Full Text] [Related]
8. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes.
Xu P; Ye X; Zhang Y; Yuan Q; Liu M; Wu Q; Ren G; Li D
J Diabetes Complications; 2015; 29(1):5-12. PubMed ID: 25456819
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a combination of high and low dosage of PEGylated FGF-21 in treatment of diabetes in db/db mice.
Xu P; Zhang Y; Song L; Khoso MH; Li J; Jiang X; He J; Li J; Ma X; Ren G; Li D
Biomed Pharmacother; 2016 Dec; 84():97-105. PubMed ID: 27643551
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor 21: a novel long-acting hypoglycemic drug for canine diabetes.
Jiang X; Liu S; Wang Y; Zhang R; Opoku YK; Xie Y; Li D; Ren G
Naunyn Schmiedebergs Arch Pharmacol; 2021 May; 394(5):1031-1043. PubMed ID: 33219471
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
[TBL] [Abstract][Full Text] [Related]
13. Mouse fibroblast growth factor 10: cDNA cloning, protein characterization, and regulation of mRNA expression.
Beer HD; Florence C; Dammeier J; McGuire L; Werner S; Duan DR
Oncogene; 1997 Oct; 15(18):2211-8. PubMed ID: 9393979
[TBL] [Abstract][Full Text] [Related]
14. Solid-phase N-terminus PEGylation of recombinant human fibroblast growth factor 2 on heparin-sepharose column.
Huang Z; Ye C; Liu Z; Wang X; Chen H; Liu Y; Tang L; Zhao H; Wang J; Feng W; Li X
Bioconjug Chem; 2012 Apr; 23(4):740-50. PubMed ID: 22433083
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers.
Chae SY; Chun YG; Lee S; Jin CH; Lee ES; Lee KC; Youn YS
J Pharm Sci; 2009 Apr; 98(4):1556-67. PubMed ID: 18704955
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of monomethoxypoly(ethylene glycol)-insulin conjugates.
Zhang M; Dou H; Yin L; Zhang Y; Zhu S; Yin C
Pharmazie; 2009 Mar; 64(3):190-6. PubMed ID: 19348342
[TBL] [Abstract][Full Text] [Related]
17. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents.
Mu J; Pinkstaff J; Li Z; Skidmore L; Li N; Myler H; Dallas-Yang Q; Putnam AM; Yao J; Bussell S; Wu M; Norman TC; Rodriguez CG; Kimmel B; Metzger JM; Manibusan A; Lee D; Zaller DM; Zhang BB; DiMarchi RD; Berger JP; Axelrod DW
Diabetes; 2012 Feb; 61(2):505-12. PubMed ID: 22210323
[TBL] [Abstract][Full Text] [Related]
18. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.
Youn YS; Jeon JE; Chae SY; Lee S; Lee KC
Diabetes Obes Metab; 2008 Apr; 10(4):343-6. PubMed ID: 18034839
[TBL] [Abstract][Full Text] [Related]
19. Rehmannia glutinosa (Gaertn.) DC. polysaccharide ameliorates hyperglycemia, hyperlipemia and vascular inflammation in streptozotocin-induced diabetic mice.
Zhou J; Xu G; Yan J; Li K; Bai Z; Cheng W; Huang K
J Ethnopharmacol; 2015 Apr; 164():229-38. PubMed ID: 25698243
[TBL] [Abstract][Full Text] [Related]
20. (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.
McClean PL; Irwin N; Hunter K; Gault VA; Flatt PR
Br J Pharmacol; 2008 Nov; 155(5):690-701. PubMed ID: 18695644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
